Scarica l'app Stockscreener
30.40
4.04%
1.18
Dopo l'orario di chiusura:
30.87
0.47
+1.55%
Precedente Chiudi:
$29.22
Aprire:
$29.45
Volume 24 ore:
1.84M
Relative Volume:
2.68
Capitalizzazione di mercato:
$2.00B
Reddito:
-
Utile/perdita netta:
$-137.95M
Rapporto P/E:
-12.05
EPS:
-2.5226
Flusso di cassa netto:
$-107.11M
1 W Prestazione:
+2.39%
1M Prestazione:
+52.00%
6M Prestazione:
+77.05%
1 anno Prestazione:
+237.40%
Intervallo 1D:
$29.06
$30.99
Intervallo di 1 settimana:
$28.62
$30.99
Portata 52W:
$8.98
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-468-4219
Indirizzo
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
30.40 | 1.92B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Iniziato | BofA Securities | Buy |
| 2026-01-29 | Iniziato | Citizens JMP | Mkt Perform |
| 2026-01-08 | Iniziato | BTIG Research | Buy |
| 2025-12-18 | Iniziato | Mizuho | Neutral |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Bicara Therapeutics Inc stock hits all-time high at 29.92 USD - Investing.com
Price to earnings forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Citizens upgrades Bicara Therapeutics stock price target on CRC data - Investing.com UK
Citizens upgrades Bicara Therapeutics stock price target on CRC data By Investing.com - Investing.com South Africa
BICARA THERAPEUTICS INC (BCAX) Stock Chart - ChartMill
Bicara Therapeutics stock hits 52-week high at 27.98 USD - Investing.com
Bicara Therapeutics stock hits 52-week high at 27.98 USD By Investing.com - Investing.com Australia
BCAXBicara Therapeutics Inc Volatility & Greeks - Finviz
Bicara Therapeutics Inc. Actuals & Estimates (BOATS:BCAX) - TradingView
Bicara Therapeutics Inc. Actuals & Estimates (NASDAQ:BCAX) - TradingView
Form 144 BICARA THERAPEUTICS INC. For: 25 June By Investing.com - Investing.com Nigeria
BCAX (NASDAQ: BCAX) affiliate to offer 50,000 shares after option exercise - Stock Titan
BCAX Forecast — Price Target — Prediction for 2027 - TradingView
Bicara Therapeutics Inc (BCAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bicara Therapeutics stock hits 52-week high at 24.29 USD - Investing.com
Bicara Therapeutics stock hits 52-week high at 24.29 USD By Investing.com - Investing.com South Africa
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - AOL.com
Bicara Therapeutics Inc (BCAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bicara Therapeutics Inc (BCAX) Institutional Confidence - TradingKey
Bicara Therapeutics Inc (BCAX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bicara Therapeutics Inc (BCAX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bicara Therapeutics Inc (BCAX) Valuation: PE, PB & Fair Value Analysis - TradingKey
[Bicara Therapeutics (BCAX) Rises 1.35% as Stock Holds Above Key SupportTICK Divergence - Město Břeclav
Bicara Therapeutics Inc (BCAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bicara Therapeutics Inc (BCAX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bicara Therapeutics Inc (BCAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bicara Therapeutics Inc. appoints Chris Sarchi as Chief Commercial Officer to drive commercial growth - Traders Union
Bicara Therapeutics CEO Sells 15,000 Shares: Insider Transaction Under ScrutinyDividend Earnings Report - newsline.com
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - The Motley Fool
Bicara Therapeutics Inc. joins ACS CAN in efforts to shape evidence-based cancer policies - Traders Union
Bicara Therapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics (BCAX) director receives 19,475-share option tied to RA Capital - Stock Titan
[8-K] Bicara Therapeutics Inc. Reports Material Event - Stock Titan
Bicara Therapeutics Inc. presents three year Phase 1b results for ficerafusp alfa combination in HPV negative HNSCC - Traders Union
BCAX Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Clinical Pipeline ProgressDebt Analysis Report - newsline.com
Bicara Therapeutics (BCAX) Edges Lower, Tests Key Support LevelsCumulative Volume - newsline.com
BCAX Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre‑Revenue Biotech’s R&D SpendingFinancial Data - newsline.com
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating By Investing.com - Investing.com India
Bicara (BCAX) Q4 2025 Earnings Transcript - AOL.com
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):